Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) ...
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Iovance Biotherapeutics call volume above normal and directionally bullish
Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 9,622 calls trading, 2x expected, and implied vol increasing almost 27 ...
Zacks.com on MSN1d
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in ...
Zacks.com on MSN9h
Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet
The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...
Philadelphia biotech firm backed by more than $130M names new CEO
A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.
Arcutis Biotherapeutics’ (ARQT) Buy Rating Reiterated at Guggenheim
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research report issued on Monday,Benzinga reports. Other equities ...